SCHEMBL25205663

SCHEMBL25205663

O=C(C=Cc1ccc(OC(CCC2=CCCCC2)C(=O)O)cc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HPGD P15428 1/20 0.48
MAPT P10636 6/20 0.46
KMT2A Q03164 6/20 0.46
BCHE P06276 2/20 0.46
CYP3A4 P08684 2/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
MEN1 O00255 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12129966 1.00 RAB9A (0.48) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL12129980 0.96 SMN1; SMN2 (0.51) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL25193198 0.96 SMN1; SMN2 (0.51) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL12130094 0.90 PPARG (0.54) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL1343879 0.85 KMT2A (0.55) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL1343880 0.85 KMT2A (0.55) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL12812616 0.82 PPARG (0.61) RAB9ANPC1LMNAMAPTKMT2A
SCHEMBL25198813 0.82 PPARG (0.61) RAB9ANPC1LMNAMAPTKMT2A
SCHEMBL1343113 0.78 PPARG (0.59) RAB9ANPC1MAPTKMT2ANFKB1
SCHEMBL25216464 0.77 PPARG (0.61) LMNAMAPTKMT2ABCHEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B RAB9A 480/4885NPC1 1378/4885LMNA 1180/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 RAB9A 1327/4885NPC1 1908/4885LMNA 1817/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 RAB9A 1327/4885NPC1 1908/4885LMNA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.